FDA Approves Roche’s Columvi to Treat Diffuse Large B-Cell Lymphoma in Adults
- By BSTQ Staff
The U.S. Food and Drug Administration (FDA) has approved Roche’s Columvi, an antibody-based therapy chemically known as glofitamab, to treat diffuse large B-cell lymphoma in adults who had received at least two prior lines of treatment before their cancer relapsed. Columvi’s approval is based on data from a mid-stage study that showed that 56 percent of patients treated with the therapy had no signs of cancer or had seen a significant decrease in cancer cells in the body.
References
- Sunny, ME. Roche’s Cancer Therapy Gets US FDA Nod, Heating Up Competition with AbbVie. Reuters, June 16, 2023. Accessed at www.reuters.com/business/healthcare-pharmaceuticals/roches-cancer-therapy-gets-us-fda-nod-heating-up-competition-with-abbvie-2023-06-16.
